Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top Correlated Resources
068270.KS
Top 10 Correlated ETFs
068270.KS
Top 10 Correlated Stocks
068270.KS
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 7.11K | 7.35K | 8.7K | 13.83K | 14.3K | |
| Net income per share | 2.99K | 1.96K | 2.3K | 3.82K | 4.3K | |
| Operating cash flow per share | 3.87K | 2.86K | 3.66K | 2.62K | 6.82K | |
| Free cash flow per share | 2.92K | 1.33K | 1.45K | -1.43K | 4.41K | |
| Cash per share | 4.18K | 3.99K | 4.84K | 5.22K | 9.13K | |
| Book value per share | 18.17K | 18.9K | 21.55K | 24.95K | 29.48K | |
| Tangible book value per share | 12.14K | 12.81K | 14.4K | 15.15K | 19.16K | |
| Share holders equity per share | 18.17K | 18.9K | 21.55K | 24.95K | 29.48K | |
| Interest debt per share | 4.9K | 3.97K | 3.9K | 5.85K | 5.63K | |
| Market cap | 39104.2B | 26280.34B | 20808.59B | 42461.63B | 20185B | |
| Enterprise value | 39325.91B | 26386.35B | 20757.81B | 42551.74B | 19741.03B | |
| P/E ratio | 97.92 | 100.37 | 69.93 | 83.05 | 35.1 | |
| Price to sales ratio | 41.2 | 26.76 | 18.44 | 22.96 | 10.56 | |
| POCF ratio | 75.69 | 68.78 | 43.9 | 121.06 | 22.15 | |
| PFCF ratio | 100.53 | 148.5 | 110.77 | -222.73 | 34.24 | |
| P/B Ratio | 16.13 | 10.41 | 7.45 | 12.73 | 5.12 | |
| PTB ratio | 16.13 | 10.41 | 7.45 | 12.73 | 5.12 | |
| EV to sales | 41.44 | 26.87 | 18.39 | 23.01 | 10.33 | |
| Enterprise value over EBITDA | 63.33 | 56.5 | 37.87 | 51.29 | 20.6 | |
| EV to operating cash flow | 76.12 | 69.06 | 43.79 | 121.32 | 21.67 | |
| EV to free cash flow | 101.1 | 149.1 | 110.5 | -223.2 | 33.48 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | |
| Free cash flow yield | 0.01 | 0.01 | 0.01 | 0 | 0.03 | |
| Debt to equity | 0.09 | 0.04 | 0.05 | 0.06 | 0.04 | |
| Debt to assets | 0.26 | 0.26 | 0.25 | 0.32 | 0.29 | |
| Net debt to EBITDA | 0.36 | 0.23 | -0.09 | 0.11 | -0.46 | |
| Current ratio | 2.62 | 2.45 | 2.72 | 2.38 | 2.54 | |
| Interest coverage | 39.94 | 23.81 | 34.92 | 94.91 | 91.35 | |
| Income quality | 1.29 | 1.46 | 1.59 | 0.69 | 1.58 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.02 | 0.02 | 0.01 | 0.03 | |
| Research and developement to revenue | 0.06 | 0.09 | 0.1 | 0.09 | 0.07 | |
| Intangibles to total assets | 0.28 | 0.26 | 0.27 | 0.28 | 0.27 | |
| Capex to operating cash flow | -0.25 | -0.54 | -0.6 | -1.54 | -0.35 | |
| Capex to revenue | -0.13 | -0.21 | -0.25 | -0.29 | -0.17 | |
| Capex to depreciation | -1.23 | -1.62 | -1.8 | -3.02 | -1.46 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | |
| Graham number | 34.99K | 28.88K | 33.36K | 46.34K | 53.42K | |
| ROIC | 0.18 | 0.12 | 0.12 | 0.18 | 0.17 | |
| Return on tangible assets | 0.16 | 0.1 | 0.1 | 0.14 | 0.14 | |
| Graham Net | -1.71K | -2.2K | -1.58K | -5.25K | -850.02 | |
| Working capital | 998.36B | 986.39B | 1130.11B | 1460.98B | 1866.37B | |
| Tangible asset value | 1619.72B | 1710.44B | 1866.94B | 2024.65B | 2561.19B | |
| Net current asset value | 728B | 756.63B | 800.61B | 925.21B | 1453.11B | |
| Invested capital | 0.26 | 0.2 | 0.18 | 0.23 | 0.19 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 27.5B | 27.33B | 38.33B | 33.96B | 57.34B | |
| Average inventory | 293.08B | 274.35B | 347.26B | 385.58B | 483.01B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 29.3 | 17.45 | 31.27 | 14.97 | 36.37 | |
| Days of inventory on hand | 279.46 | 137.53 | 226.23 | 169.99 | 261.5 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 12.46 | 20.92 | 11.67 | 24.38 | 10.04 | |
| Inventory turnover | 1.31 | 2.65 | 1.61 | 2.15 | 1.4 | |
| ROE | 0.16 | 0.1 | 0.11 | 0.15 | 0.15 | |
| Capex per share | -956.73 | -1.54K | -2.21K | -4.05K | -2.41K |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 3.16K | 2.94K | 4.55K | 4.03K | 4.32K | |
| Net income per share | 919.18 | 992 | 882.04 | 867.78 | 1.33K | |
| Operating cash flow per share | 1.64K | 1.51K | 2.69K | 102.75 | -1.73K | |
| Free cash flow per share | 979.96 | 700.22 | 2.14K | -364.31 | -2.23K | |
| Cash per share | 6.01K | 7.03K | 8.93K | 0 | 4.2K | |
| Book value per share | 26.78K | 27.92K | 28.85K | 27.45K | 28.26K | |
| Tangible book value per share | 16.76K | 17.56K | 18.75K | 28.41K | 18.04K | |
| Share holders equity per share | 26.78K | 27.92K | 28.85K | 27.45K | 28.26K | |
| Interest debt per share | 5.47K | 5.53K | 5.46K | 38.92 | 5.81K | |
| Market cap | 35940.79B | 34749.55B | 27044.39B | 23424.81B | 24653.54B | |
| Enterprise value | 35879.15B | 34570.04B | 26600.42B | 23424.81B | 24912.19B | |
| P/E ratio | 71.59 | 64.12 | 56.12 | 49.41 | 33.6 | |
| Price to sales ratio | 83.24 | 86.67 | 43.49 | 42.54 | 41.36 | |
| POCF ratio | 160.52 | 167.97 | 73.51 | 1.67K | -103.4 | |
| PFCF ratio | 268.62 | 363.33 | 92.73 | -470.75 | -79.88 | |
| P/B Ratio | 9.83 | 9.11 | 6.86 | 6.25 | 6.32 | |
| PTB ratio | 9.83 | 9.11 | 6.86 | 6.25 | 6.32 | |
| EV to sales | 83.1 | 86.22 | 42.77 | 42.54 | 41.79 | |
| Enterprise value over EBITDA | 173.98 | 143.71 | 132.72 | 118.3 | 87.36 | |
| EV to operating cash flow | 160.24 | 167.1 | 72.31 | 1.67K | -104.48 | |
| EV to free cash flow | 268.16 | 361.46 | 91.21 | -470.75 | -80.72 | |
| Earnings yield | 0 | 0 | 0 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0.01 | 0 | -0.01 | |
| Debt to equity | 0.05 | 0.05 | 0.04 | 0 | 0.05 | |
| Debt to assets | 0.28 | 0.29 | 0.29 | 0.31 | 0.29 | |
| Net debt to EBITDA | -0.3 | -0.75 | -2.22 | 0 | 0.91 | |
| Current ratio | 2.77 | 2.54 | 2.54 | 2.31 | 2.52 | |
| Interest coverage | 76.33 | 88.5 | 124.76 | 26.77 | 99.71 | |
| Income quality | 1.78 | 1.53 | 3.05 | 0.12 | -1.3 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.18 | 0.21 | -0.32 | 0.2 | 0.17 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.28 | 0.28 | 0.27 | 0 | 0.27 | |
| Capex to operating cash flow | -0.4 | -0.54 | -0.21 | -4.55 | 0.29 | |
| Capex to revenue | -0.21 | -0.28 | -0.12 | -0.12 | -0.12 | |
| Capex to depreciation | -1.72 | -1.99 | -1.33 | -1.17 | -1.23 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 23.54K | 24.96K | 23.93K | 23.15K | 29.06K | |
| ROIC | 0.04 | 0.04 | 0.05 | 0.03 | 0.04 | |
| Return on tangible assets | 0.03 | 0.03 | 0.03 | 0.02 | 0.04 | |
| Graham Net | -3.18K | -2.64K | -831.9 | -12.86K | -5.08K | |
| Working capital | 1704.21B | 1754.88B | 1866.37B | 1705.06B | 1803.82B | |
| Tangible asset value | 2288.48B | 2398.13B | 2561.19B | 0 | 2491.24B | |
| Net current asset value | 1188.72B | 1300.54B | 1453.11B | 1251.23B | 1339.43B | |
| Invested capital | 0.2 | 0.2 | 0.19 | 0 | 0.21 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 10.91 | 36.02 | 23.84 | 0 | 26.46 | |
| Days of inventory on hand | 206.62 | 320.88 | 171.4 | 0 | 224.46 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 8.25 | 2.5 | 3.78 | 0 | 3.4 | |
| Inventory turnover | 0.44 | 0.28 | 0.53 | 0 | 0.4 | |
| ROE | 0.03 | 0.04 | 0.03 | 0.03 | 0.05 | |
| Capex per share | -659.95 | -814.43 | -558.19 | -467.06 | -508.3 |
Frequently Asked Questions
What is Celltrion, Inc. stock symbol ?
Celltrion, Inc. is a US stock and trading under the symbol 068270.KS
What is Celltrion, Inc. stock quote today ?
Celltrion, Inc. stock price is $175500 today.
Is Celltrion, Inc. stock public?
Yes, Celltrion, Inc. is a publicly traded company.
Company Profile
- Volume Average 389.03K
- Market Capitalization 24264.98B
- Employee 2.03K
- Headquarters Incheon,US
- IPO Date 2005-07-19
-
Website
https://www.celltrion.com 
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.
